Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05582707 · ClinicalTrials.gov registry record · Phase 2
Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05582707 is a Phase 2 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 1 participants.
The verdict
NCT05582707, a Phase 2 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an exploratory single-center prospective study of 20 subjects with primary basal ganglia ICH who will receive early MIPS in combination with perioperative pioglitazone treatment. Outcomes will be compared to matched subjects with basal ganglia ICH who undergo MIPS alone as part of the ENRICH trial. This study will take approximately two years to complete.
Interventions
- DRUG Pioglitazone 15mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-05-08 |
| Est. Completion | 2025-12-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05582707
The ClinicalTrials.gov registry entry for NCT05582707 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pioglitazone 15mg is the first listed.
NCT05582707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05582707 about?
NCT05582707 is a clinical study titled "Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone". This is an exploratory single-center prospective study of 20 subjects with primary basal ganglia ICH who will receive early MIPS in combination with perioperative pioglitazone treatment. Outcomes will be compared to matched subjects with basal ganglia ICH who undergo MIPS alone as part of the ENRICH...
What is the current status of trial NCT05582707?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2023-05-08. Estimated completion is 2025-12-25.
What interventions are being tested in trial NCT05582707?
The interventions under investigation include: Pioglitazone 15mg (DRUG).
Who is sponsoring clinical trial NCT05582707?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.